JAMES TANSINDA: Open Payments
NPI 1184690141 · CATONSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,038 in 45 payments from 15 companies in 2025. Trend: 2023 $1,580 · 2024 $1,508 · 2025 $1,038
Food & beverage: $1,038
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $240 |
| AstraZeneca Pharmaceuticals LP | 9 | $170 |
| Sumitomo Pharma America, Inc. | 5 | $112 |
| Exact Sciences Corporation | 4 | $91 |
| GlaxoSmithKline, LLC. | 4 | $82 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $67 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Dexcom, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Lundbeck LLC | 1 | $30 |
Products named: Ozempic, BREZTRI, GEMTESA, Cologuard Collection Kit, TRELEGY ELLIPTA, Kerendia, JARDIANCE, Dexcom G6 Transmitter.
Industry payments across MD — which companies pay providers there.
